Marc Rubin - Titan Pharmaceuticals Executive Chairman of the Board
TTNP Stock | USD 6.97 0.04 0.57% |
Chairman
Dr. Marc Rubin, M.D., is Executive Chairman of the Board of Titan Pharmaceuticals, Inc. Marc Rubin, M.D. served as our President and Chief Executive from October 2007 until December 2008 and was reengaged as our Executive Chairman in May 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG since joining the Company in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of increasing responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College since 2009.
Age | 63 |
Tenure | 15 years |
Professional Marks | Ph.D |
Phone | 650 244 4990 |
Web | https://www.titanpharm.com |
Titan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.749) % which means that it has lost $0.749 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3914) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 5 records | CHAIRMAN Age | ||
Christoph Westphal | Salarius Pharmaceuticals | 47 | |
David Dodd | GeoVax Labs | 74 | |
Quang Pham | Cadrenal Therapeutics Common | 59 | |
Samuel Reich | SAB Biotherapeutics | 49 | |
David Young | Processa Pharmaceuticals | 63 |
Management Performance
Return On Equity | -1.39 | ||||
Return On Asset | -0.75 |
Titan Pharmaceuticals Leadership Team
Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Rubin, Executive Chairman of the Board | ||
Rajinder Kumar, Director | ||
Brian Crowley, Senior Administration | ||
Sunil Bhonsle, President, Secretary and Director | ||
James McNab, Director | ||
Federico Recli, Director | ||
David MacFarlane, Independent Director | ||
Joseph Akers, Director | ||
Eurelio Cavalier, Independent Director | ||
Marc MD, Ex Director | ||
David Lazar, Principal Officer | ||
Scott Smith, Director | ||
Joe Schrei, Executive Operations | ||
Katherine BeebeDeVarney, COO President | ||
Ley Smith, Independent Director | ||
Dane Hallberg, Executive Vice President and Chief Commercial Officer | ||
Jennifer Kiernan, Executive Coordinator | ||
Victor Bauer, Independent Director | ||
Seghi Recli, Lead Director | ||
Mike Fritz, National Director |
Titan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.39 | ||||
Return On Asset | -0.75 | ||||
Operating Margin | (39.55) % | ||||
Current Valuation | 178.21 K | ||||
Shares Outstanding | 914.23 K | ||||
Shares Owned By Insiders | 45.46 % | ||||
Shares Owned By Institutions | 5.51 % | ||||
Number Of Shares Shorted | 10.18 K | ||||
Price To Earning | (3.60) X | ||||
Price To Book | 1.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Titan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Titan Pharmaceuticals' short interest history, or implied volatility extrapolated from Titan Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.